Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Selective sodium glucose cotransporter-2 inhibitor (SGLT2i) treatment promotes urinary glucose excretion, thereby reducing blood glucose as well as body weight. However, only limited body weight reductions are achieved with SGLT2i treatment. Hyperphagia is reportedly one of the causes of this limited weight loss. However, the effects of SGLT2i treatment on systemic energy expenditure have not been fully elucidated. Herein, we investigated the acute effects of dapagliflozin, a SGLT2i, on systemic energy expenditure in mice. Eighteen hours after dapagliflozin treatment oxygen consumption and brown adipose tissue (BAT) expression of ucp1, a thermogenesis-related gene, were significantly decreased as compared to those after vehicle treatment. In addition, dapagliflozin significantly suppressed norepinephrine (NE) turnover in BAT and c-fos expression in the rostral raphe pallidus nucleus (rRPa) which contains the sympathetic premotor neurons responsible for thermogenesis. These findings indicate that the dapagliflozin-mediated acute decrease in energy expenditure involves a reduction in BAT thermogenesis via decreased sympathetic nerve activity from the rRPa. Furthermore, common hepatic branch vagotomy abolished the reductions in ucp1 expression and NE contents in BAT and c-fos expression in the rRPa. In addition, alterations in hepatic carbohydrate metabolism, such as decreases in glycogen contents and upregulation of phosphoenolpyruvate carboxykinase, manifested prior to the suppression of BAT thermogenesis, e.g. 6 hours after dapagliflozin treatment. Collectively, these results suggest that SGLT2i treatment acutely suppresses energy expenditure in BAT via regulation of an inter-organ neural network consisting of the common hepatic vagal branch and sympathetic nerves.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the rationale behind SGLT-2i causing a decrease in BP (systolic BP: 5mmHg, diastolic BP: 2mmHg on average)9 without a change in the heart rate remains unknown.10–12”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698 · cited 1×
“However, weight loss degrees after SGLT2i treatment appear to be much less than those predicted from the excreted glucose amounts in both human and animal studies [4,5].”
BackgroundSGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Central control of thermogenesis in mammals
Morrison, S. F., Nakamura, K., & Madden, C. J. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.041848 · Cited by 424 · cited 1×
“Activation of sympathetic nerves to BAT is responsible for UCP1 and PGC1α up-regulation, followed by enhancement of BAT thermogenesis [13].”
BackgroundSelf-citationEnergy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Effect of Diet and Cold Exposure on Norepinephrine Turnover in Brown Adipose Tissue of the Rat
Young, J. B., Saville, E., Rothwell, N. J., Stock, M. J., & Landsberg, L. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110541 · Cited by 355 · cited 1×
“Therefore, we first examined norepinephrine (NE) turnover in BAT, as this result is known to reflect sympathetic activity to BAT [14].”
BackgroundThe Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Vallon, V. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-110046 · Cited by 348 · cited 4×
“Therefore, the development of therapeutic strategies for T2D that include decreasing body weight has long been awaited.”
BackgroundInfluentialImplications of nonshivering thermogenesis for energy balance regulation in humans
van Marken Lichtenbelt, W. D., & Schrauwen, P. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00652.2010 · Cited by 311
The Rostral Raphe Pallidus Nucleus Mediates Pyrogenic Transmission from the Preoptic Area
Nakamura, K., Matsumura, K., Kaneko, T., Kobayashi, S., Katoh, H., & Negishi, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04600.2002 · Cited by 275 · cited 1×
“Therefore, we next examined the neural activity in the rRPa (Fig 2H), which contains the putative sympathetic premotor neurons responsible for thermogenesis in BAT [15].”
BackgroundSelf-citationNeuronal Pathway from the Liver Modulates Energy Expenditure and Systemic Insulin Sensitivity
Uno, K., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., Imai, J., Hasegawa, Y., Gao, J., Kaneko, K., Iwasaki, H., et al. (2006) · Science · doi:10.1126/science.1126010 · Cited by 262 · cited 3×
“Furthermore, we previously showed that adenovirus-mediated expression of peroxisome proliferator-activated receptor γ2 in the liver induced acute hepatic steatosis, and increased BAT thermogenesis through afferent vagal signals originating in the liver [11].”
BackgroundMethodSelf-citationRenal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217 · cited 1×
“Effects on increased urinary glucose excretion (UGE) by selective SGLT2 inhibition are not limited to blood glucose reduction in an insulin-independent manner but body weight reduction is also achieved [3].”
BackgroundDevenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212 · cited 3×
“On the other hand, it was previously reported that SGLT2i treatment induced hyperphagia but did not affect oxygen consumption in ad libitum fed rats [6,18].”
BackgroundAnatomy and function of sensory hepatic nerves
Berthoud, H. (2004) · The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology · doi:10.1002/ar.a.20088 · Cited by 197 · cited 1×
“Dissecting the common hepatic vagal branch denervates not only the liver, but also certain parts of the distal stomach and duodenum [21].”
BackgroundYokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195 · cited 1×
“On the other hand, it was previously reported that SGLT2i treatment induced hyperphagia but did not affect oxygen consumption in ad libitum fed rats [6,18].”
BackgroundIzumida, Y., Yahagi, N., Takeuchi, Y., Nishi, M., Shikama, A., Takarada, A., Masuda, Y., Kubota, M., Matsuzaka, T., Nakagawa, Y., et al. (2013) · Nature Communications · doi:10.1038/ncomms3316 · Cited by 119 · cited 3×
“In previous studies including ours, metabolic alterations in the liver were found to modulate sympathetic nerve activities to BAT [10,11] and WAT [16,17].”
BackgroundSelf-citationTahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0713-z · Cited by 112 · cited 1×
“For instance, ipragliflozin, another highly selective SGLT2i, did not affect sucrose, maltose, glucose or fructose contents of the upper small intestine in mice [22].”
BackgroundTsukita, S., Yamada, T., Uno, K., Takahashi, K., Kaneko, K., Ishigaki, Y., Imai, J., Hasegawa, Y., Sawada, S., Ishihara, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.11.006 · Cited by 98 · cited 4×
“We further showed that activation of glucokinase enhances hepatic glycogen accumulation, leading to suppression of BAT thermogenesis via regulation of sympathetic nerve activity [10].”
BackgroundMethodInfluentialSelf-citationNagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., Honda, K., Suzuki, Y., & Kawabe, Y. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12269 · Cited by 88
Chen, L., & Leung, P. S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12064 · Cited by 72 · cited 1×
“Furthermore, since SGLT2 is not expressed in the gastrointestinal tract [23], direct effects of dapagliflozin on the gastrointestinal tracts are unlikely.”
BackgroundVickers, S. P., Cheetham, S. C., Headland, K. R., Dickinson, K., Grempler, R., Mayoux, E., Mark, M., & Klein, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s58786 · Cited by 65 · cited 1×
“However, weight loss degrees after SGLT2i treatment appear to be much less than those predicted from the excreted glucose amounts in both human and animal studies [4,5].”
BackgroundUno, K., Yamada, T., Ishigaki, Y., Imai, J., Hasegawa, Y., Sawada, S., Kaneko, K., Ono, H., Asano, T., Oka, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms8940 · Cited by 65 · cited 3×
“In previous studies including ours, metabolic alterations in the liver were found to modulate sympathetic nerve activities to BAT [10,11] and WAT [16,17].”
BackgroundSelf-citationChronic mild stress alters circadian expressions of molecular clock genes in the liver
Takahashi, K., Yamada, T., Tsukita, S., Kaneko, K., Shirai, Y., Munakata, Y., Ishigaki, Y., Imai, J., Uno, K., Hasegawa, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00388.2012 · Cited by 63 · cited 1×
“Immediately after microdissection, total RNA was purified as previously described [9].”
MethodSelf-citationShibata, H., & Bukowiecki, L. J. (1987) · Journal of Applied Physiology · doi:10.1152/jappl.1987.63.2.465 · Cited by 34 · cited 1×
“As with the negative energy balance induced by SGLT2i treatment, fasting reduces systemic oxygen consumption [20].”
BackgroundEffects of repeated cycles of fasting-refeeding on brown adipose tissue composition in mice
Desautels, M., & Dulos, R. A. (1988) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1988.255.2.e120 · Cited by 19 · cited 1×
“BAT thermogenesis also plays an important role in whole-body energy expenditure [12].”
BackgroundNiijima, A. (1988) · Physiology & Behavior · doi:10.1016/0031-9384(88)90332-0 · Cited by 11 · cited 1×
“The hepatoportal glucose sensing mechanism reportedly stimulates glucose utilization in peripheral tissue via a neural network consisting of afferent and efferent vagal nerves [24].”
Background
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y.-K., Yamamoto, T., Takano, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01127-z · Cited by 228
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.07.002 · Cited by 140
“Dapagliflozin was also reported to reduce some of the complications associated with NASH in rodent models.(16,17) Therefore, in the present study, we evaluated the effects of dapagliflozin for the treatment of NASH in patients with T2DM.”
Background
Metadata
- Authors
- Chiba, Y., Yamada, T., Tsukita, S., Takahashi, K., Munakata, Y., Shirai, Y., Kodama, S., Asai, Y., Sugisawa, T., Uno, K., Sawada, S., Imai, J., Nakamura, K., & Katagiri, H.
- Affiliations
- Tohoku University (JP)
- Nagoya University (JP)
- Corresponding author
- Yamada, Tetsuya
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-10
- Volume
- 11
- Issue
- 3
- Pages
- e0150756
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4786146
- OpenAlex
- W2295311043
- Cited by
- 71
- References
- 24
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 17 · 2019: 7 · 2018: 5 · 2017: 5
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (15H05932, 26293215, 26461324, 25253067, 15K09407, 26670447, 26713009)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- dapagliflozin, SGLT2 inhibitors, energy expenditure, brown adipose tissue thermogenesis, sympathetic activity, norepinephrine turnover, c-fos, hepatic vagotomy, hepatic carbohydrate metabolism, UCP1, hyperphagia, weight loss
- MeSH terms
- Uncoupling Protein 1, Sodium-Glucose Transporter 2 Inhibitors, Animals, Benzhydryl Compounds, Adipose Tissue, Brown, Energy Metabolism, Gene Expression Regulation, Glucosides, Glycogen, Ion Channels, Liver, Male, Synaptic Transmission, Vagus Nerve, Proto-Oncogene Proteins c-fos, Thermogenesis, Mitochondrial Proteins, Carbohydrate Metabolism, Sodium-Glucose Transporter 2, Mice, Midbrain Raphe Nuclei
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.